Chaya M

Nanotechnology-based medicines (nanomedicines) are emerging as a major innovation in the field of healthcare, combining nanoscale materials with pharmaceutical sciences to improve diagnosis, treatment, and prevention of diseases. This review explores the market potential and consumer acceptance of nanotechnology-based medicines. The nanomedicine market is expected to grow substantially due to increased prevalence of chronic diseases, advancements in targeted drug delivery, and rising investment in research and development.4 However, consumer acceptance is influenced by factors such as safety concerns, cost, ethical implications, and regulatory uncertainty. This paper highlights market dynamics, regional growth, challenges, and recommendations to improve acceptance and commercialization of nanomedicine. Despite these advancements, widespread consumer acceptance of nanomedicines remains influenced by several factors, including safety concerns, ethical considerations, high production costs, and lack of standardized regulatory frameworks. Public perception and awareness also play a critical role in determining market success. Furthermore, regional disparities in access to advanced healthcare technologies, limited infrastructure, and challenges in large-scale manufacturing hinder commercialization. This paper highlights current trends in nanomedicine development, market drivers, and barriers affecting its acceptance. It also discusses the potential impact of nanotechnology on personalized medicine and the pharmaceutical industry’s evolution. To enhance consumer trust and promote broader adoption, there is a need for transparent regulatory policies, ethical guidelines, and extensive clinical evaluation to ensure safety and efficacy. ed medicines hold the review concludes that with proper governance and technological refinement, nanotechnology-bas immense promise for transforming global healthcare systems.

OTC medications are essential for increasing access to healthcare since they allow people to self-medicate for mild ailments. In this project, the marketing difficulties of over-the-counter herbal and allopathic medications are compared. Despite being largely regarded as safe, natural, and culturally acceptable, herbal over-the-counter medications (OTCs) confront several challenges, including slower onset of action, clinical validation, standardization, and regulatory compliance. The strong scientific backing, stringent regulation, and quick therapeutic results of allopathic over-the-counter medications, on the other hand, make them vulnerable to price pressure, restrictions on promotions, and growing customer demand for "natural" substitutes. The study draws attention to variations in pricing policies, promotional restrictions, consumer perception, and regulatory frameworks. Antihistamine, antipyretic, antitussive, and NSAID case comparisons show differences in adverse effects, adherence, and market share. For both herbal and allopathic over-the-counter marketers to be successful in the cutthroat healthcare industry, they must ultimately embrace flexible tactics, guarantee evidence-based claims, and cultivate consumer trust. For both industries to thrive sustainably, patient-centered strategies, innovation, and responsible promotion are crucial.

The main objective of this study is to improve the physicochemical stability, swelling and drug release pattern of the polymers in biological condition by Hybridization. In this study, interpenetrating polymer network (IPN) of acrylamide grafted ghatti gum (Am-g-GG) and poly vinyl alcohol (PVA) was developed by emulsion crosslinking method. Glutaraldehyde was used as the crosslinking agent. Experiments were performed according to a 23 factorial design to evaluate the effects of GG:PVA ratio, Glutaraldehyde and drug loading percentage on the percent Drug entrapment efficiency, percentage of Swelling at pH 1.2 & pH 6.8 and percentage Cumulative drug release. The effect of the three independent variables on the response variables was studied by response surface plots and contour plots generated by the Design-Expert software. The desirability function was used to optimize the response variables. The compatibility between Miglitol and the excipients was confirmed by differential FTIR spectroscopy analysis. The prepared IPN microspheres showed well controlled release characteristics and continued to drug release following a diffusion-controlled release pattern. The drug release was for a prolonged time without collapsing the IPN matrix. The observed responses taken were in good agreement with the experimental values. Thus, Miglitol IPN microspheres were produced with fewer experimental trials, and a patient compliant product with good stability was achieved with the concept of formulation by design.